Pancreatic cancer risk (GLP-1 myth check)

This is one of the most persistent GLP-1 fears, and it is worth separating what the labels actually warn about from what people have heard. The boxed warning on semaglutide, tirzepatide and liraglutide products concerns thyroid C-cell tumors seen in rodents — the Saxenda label states plainly that whether the drug causes those tumors in humans is unknown, and contraindicates it in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Acute pancreatitis appears separately, as a warning, not a boxed one. Pancreatic cancer is not on either list.

The concern arose because the pancreas is where GLP-1 receptors do some of their work, and because inflammation of an organ over years is a recognized cancer pathway. It was a reasonable hypothesis to test. Testing it requires long follow-up in large populations, which is exactly what the cardiovascular outcomes trials provided.

SELECT is the largest of those in people without diabetes: 17,604 adults with overweight or obesity and established cardiovascular disease, followed for years on semaglutide 2.4 mg or placebo, published in the New England Journal of Medicine in 2023. It reported a 20% reduction in major cardiovascular events and did not surface a pancreatic-cancer signal. The LEADER and SUSTAIN-6 diabetes outcome trials add thousands more patient-years.

The common confusion is reading “no signal found” as “proven impossible.” Pancreatic cancer is uncommon and slow to appear, so even large trials have limits on what they can rule out, and honest reporting says so. What the evidence supports today is that the drugs have not produced the excess cases the early hypothesis predicted — not that the question is permanently closed.

Worth asking your clinician: whether you have a personal or family history that changes the calculus, what symptoms of pancreatitis to watch for during titration, and whether a prior episode of pancreatitis rules the class out for you. Our pancreatitis-history safety review and SELECT trial page go deeper.